The role of p53 status on the synergistic effect of CKD-602 and cisplatin on oral squamous cell carcinoma cell lines
The purpose of this study was to evaluate the synergistic apoptotic effect of CKD-602 in combination with cisplatin on different p53 statuses of oral squamous cell carcinoma (OSCC) cell lines, YD-8, YD-9, and YD-38. MTT assays were used to evaluate the inhibitory effect of the treatments modality on cell growth. The combination index was calculated using CompuSyn software. Detection of cell death was carried out using the propidium iodide (PI)/RNase staining assay, Annexin V/PI double staining assay, and Western blotting. Combination treatment using CKD-602 and cisplatin inhibited proliferation and increased the apoptotic effect on the three OSCC cell lines. Apoptotic cell death was detected in the cell lines, and significant synergistic effects of CKD-602 in combination with cisplatin were observed despite the differences in p53 status. From these results, it was suggested that the combination of CKD-602 with cisplatin might be a potential therapeutic strategy for OSCC. In particular, cell line-specific therapy is necessary because of the differences in treatment response based on p53 status.
KeywordsOral squamous cell carcinoma CKD-602 Cisplatin Apoptosis p53
This work was supported by the SNUBH Research Fund (Grant No. 02-2014-018).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest related to this work.
- 1.Korea Central Cancer Registry NCC (2016) Annual report of cancer statistics in Korea in 2014. Ministry of Health and WelfareGoogle Scholar
- 6.Bundela S, Sharma A, Bisen PS (2015) Potential compounds for oral cancer treatment: resveratrol, nimbolide, lovastatin, bortezomib, vorinostat, berberine, pterostilbene, deguelin, andrographolide, and colchicine. PLoS ONE 10(11):e0141719. https://doi.org/10.1371/journal.pone.0141719 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Qi X, Xu W, Xie J, Wang Y, Han S, Wei Z, Ni Y, Dong Y, Han W (2016) Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-kappaB/HIF-1alpha signal axis. Sci Rep 6:35788. https://doi.org/10.1038/srep35788 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM (1979) Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63(9–10):1527–1531Google Scholar
- 13.Chen S, Hu H, Miao S, Zheng J, Xie Z, Zhao H (2017) Anti-tumor effect of cisplatin in human oral squamous cell carcinoma was enhanced by andrographolide via upregulation of phospho-p53 in vitro and in vivo. Tumour Biol 39(5):1010428317705330. https://doi.org/10.1177/1010428317705330 CrossRefPubMedGoogle Scholar
- 14.Crul M (2003) CKD-602. Chong Kun Dang. Curr Opin Investig Drugs (Lond, Engl: 2000) 4(12):1455–1459Google Scholar
- 16.Ok YJ, Myoung H, Kim YK, Lee JH, Kim MJ, Yun PY (2009) Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines. Oral Oncol 45(3):266–272. https://doi.org/10.1016/j.oraloncology.2008.05.001 CrossRefPubMedGoogle Scholar
- 19.Lim S, Cho BC, Jung JY, Kim GM, Kim SH, Kim HR, Kim HS, Lim SM, Park JS, Lee JH, Kim D, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Kim JH (2013) Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer (Amst Neth) 80(3):313–318. https://doi.org/10.1016/j.lungcan.2013.02.009 CrossRefGoogle Scholar
- 20.Hong J, Jung M, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH (2012) Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol 69(1):215–220. https://doi.org/10.1007/s00280-011-1689-6 CrossRefPubMedGoogle Scholar
- 21.Chan BA, Coward JI (2013) Chemotherapy advances in small-cell lung cancer. J Thorac Dis 5(Suppl 5):S565–S578. https://doi.org/10.3978/j.issn.2072-1439.2013.07.43 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57(19):4285–4300PubMedGoogle Scholar
- 27.Tao H, Zhu Y, Wang H, Lai B, Zhang C, Zhan X, Wang Y, Yang X, Yue W, Zhang H (2008) [Effects of p53 gene on drug resistance in human lung cancer cell lines]. Zhongguo fei ai za zhi = Chinese. J Lung Cancer 11(2):157–164. https://doi.org/10.3779/j.issn.1009-3419.2008.02.001 CrossRefGoogle Scholar
- 29.Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26(10):870–877. https://doi.org/10.1002/hed.20029 CrossRefPubMedGoogle Scholar
- 30.Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, Hanash SM, Carey TE, Wolf GT (1997) p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of veterans affairs laryngeal cancer cooperative study group. Arch Otolaryngol—Head Neck Surg 123(6):605–609CrossRefPubMedGoogle Scholar
- 32.Piaskowski S, Zawlik I, Szybka M, Kulczycka-Wojdala D, Stoczynska-Fidelus E, Bienkowski M, Robak T, Kusinska R, Jesionek-Kupnicka D, Kordek R, Rieske P, Liberski PP (2010) Detection of p53 mutations in different cancer types is improved by cDNA sequencing. Oncol Lett 1(4):717–721. https://doi.org/10.3892/ol_00000125 CrossRefPubMedPubMedCentralGoogle Scholar